Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
The success of Mycobacterium tuberculosis (Mtb), the infectious agent of tuberculosis (TB), lies in its ability to primarily infect, reside, and multiply in the lungs of patients. Mtb infects white blood cells termed alveolar macrophages and hides from the host immune response as well as from many antibiotics used for treatment, creating additional challenges for anti-TB drug discovery. With the increasing prevalence of multi- and extremely- drug-resistant tuberculosis in several countries, there is a pressing need for new drugs against Mtb. The objective of this study is to progress through pre-clinical development a series of lead compounds against Mtb found to be highly effective within human macrophage. We will decipher the compound’s mode of action and try to understand the basis for these compound’s exhibition of greater potency against Mtb inside the macrophages. The results of this project can be used to identify novel compounds in the treatment against tuberculosis in Canada and worldwide, fulfilling the mission of our partner organization, B.C. Lung Association. Additionally, the path to developing a new drug against tuberculosis can be expedited to clinical trials through our company partner, Novateur.
Novateur Ventures Inc
University of British Columbia
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.